RU2695358C2 - Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли - Google Patents
Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли Download PDFInfo
- Publication number
- RU2695358C2 RU2695358C2 RU2016118282A RU2016118282A RU2695358C2 RU 2695358 C2 RU2695358 C2 RU 2695358C2 RU 2016118282 A RU2016118282 A RU 2016118282A RU 2016118282 A RU2016118282 A RU 2016118282A RU 2695358 C2 RU2695358 C2 RU 2695358C2
- Authority
- RU
- Russia
- Prior art keywords
- pain
- adenosine
- compound
- mice
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 59
- 208000002193 Pain Diseases 0.000 title claims abstract description 50
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 16
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 14
- 125000006239 protecting group Chemical group 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical class NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 7
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 229910052727 yttrium Inorganic materials 0.000 claims abstract description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims abstract description 3
- 150000003835 adenosine derivatives Chemical class 0.000 claims abstract 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract 2
- 102000007371 Ataxin-3 Human genes 0.000 claims description 30
- 108010032947 Ataxin-3 Proteins 0.000 claims description 30
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 26
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 18
- -1 (thienyl) methyl group Chemical group 0.000 claims description 17
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 16
- 239000000460 chlorine Substances 0.000 claims description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 11
- 229960005305 adenosine Drugs 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 208000001640 Fibromyalgia Diseases 0.000 claims description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- 208000000112 Myalgia Diseases 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 208000013465 muscle pain Diseases 0.000 claims description 9
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- RAVKMGSIHFLQJU-UHFFFAOYSA-N (5-bromothiophen-2-yl)methanamine Chemical compound NCC1=CC=C(Br)S1 RAVKMGSIHFLQJU-UHFFFAOYSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- QUBQAOONZJWWHN-HPDNKFCTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(5-chlorothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=CC=C(S1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N QUBQAOONZJWWHN-HPDNKFCTSA-N 0.000 claims description 4
- NMCXSKQZGXWJCZ-PMXXHBEXSA-N (2r,3r,4s,5r)-2-[6-[(5-bromothiophen-2-yl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3SC(Br)=CC=3)=C2N=C1 NMCXSKQZGXWJCZ-PMXXHBEXSA-N 0.000 claims description 4
- DBRSLMCLMMFHEF-UHFFFAOYSA-N (5-bromothiophen-2-yl)methanol Chemical compound OCC1=CC=C(Br)S1 DBRSLMCLMMFHEF-UHFFFAOYSA-N 0.000 claims description 4
- QEEXZSPDLPRZEX-UHFFFAOYSA-N (5-chlorothiophen-2-yl)methanamine Chemical compound NCC1=CC=C(Cl)S1 QEEXZSPDLPRZEX-UHFFFAOYSA-N 0.000 claims description 4
- 102000014461 Ataxins Human genes 0.000 claims description 4
- 108010078286 Ataxins Proteins 0.000 claims description 4
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 102000007368 Ataxin-7 Human genes 0.000 claims description 2
- 108010032953 Ataxin-7 Proteins 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 206010028836 Neck pain Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010065016 Post-traumatic pain Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 208000007613 Shoulder Pain Diseases 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 230000012846 protein folding Effects 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 206010005063 Bladder pain Diseases 0.000 claims 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 abstract 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 230000009261 transgenic effect Effects 0.000 description 19
- 238000011830 transgenic mouse model Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 12
- 230000000202 analgesic effect Effects 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 230000008645 cold stress Effects 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000737 periodic effect Effects 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 101000822020 Homo sapiens Equilibrative nucleoside transporter 1 Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 102100021469 Equilibrative nucleoside transporter 1 Human genes 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 5
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 108010018878 adenosine transporter Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- DYCJFJRCWPVDHY-LSCFUAHRSA-N NBMPR Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(SCC=3C=CC(=CC=3)[N+]([O-])=O)=C2N=C1 DYCJFJRCWPVDHY-LSCFUAHRSA-N 0.000 description 4
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 4
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- DFETZYGISAXEEJ-FMZWZIECSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(2-bromothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1SC=CC1CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N DFETZYGISAXEEJ-FMZWZIECSA-N 0.000 description 3
- KLGJJZJEBMXGIA-HPDNKFCTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(3-bromothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC1=C(SC=C1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N KLGJJZJEBMXGIA-HPDNKFCTSA-N 0.000 description 3
- SFALKPJPYAEKKY-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-bromothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1C=C(SC=1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N SFALKPJPYAEKKY-HIDXMTOYSA-N 0.000 description 3
- OPUWCBGREITRRH-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-bromothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1C(=CSC1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N OPUWCBGREITRRH-HIDXMTOYSA-N 0.000 description 3
- CFTMGZAQILXWIX-HPDNKFCTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(5-bromothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC1=CC(=CS1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N CFTMGZAQILXWIX-HPDNKFCTSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229940045109 genistein Drugs 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- 235000006539 genistein Nutrition 0.000 description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 229920000155 polyglutamine Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000003653 radioligand binding assay Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WXHVQZUFYUSQPH-UHFFFAOYSA-N (3-bromothiophen-2-yl)methanamine Chemical compound NCC=1SC=CC=1Br WXHVQZUFYUSQPH-UHFFFAOYSA-N 0.000 description 2
- HKIISVIQBGJWLN-UHFFFAOYSA-N (4-bromothiophen-3-yl)methanamine Chemical compound NCC1=CSC=C1Br HKIISVIQBGJWLN-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FCZOVUJWOBSMSS-UHFFFAOYSA-N 5-[(6-aminopurin-9-yl)methyl]-5-methyl-3-methylideneoxolan-2-one Chemical compound C1=NC2=C(N)N=CN=C2N1CC1(C)CC(=C)C(=O)O1 FCZOVUJWOBSMSS-UHFFFAOYSA-N 0.000 description 2
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 238000012760 immunocytochemical staining Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 108091006527 nucleoside transporters Proteins 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- SLKZUJBSIKGHFU-UHFFFAOYSA-N (2-bromothiophen-3-yl)methanamine Chemical compound NCC=1C=CSC=1Br SLKZUJBSIKGHFU-UHFFFAOYSA-N 0.000 description 1
- JHXNBNCXMRCTOC-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-(thiophen-2-ylmethyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound S1C(=CC=C1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N JHXNBNCXMRCTOC-HIDXMTOYSA-N 0.000 description 1
- CSZGIBWBJCHKBU-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-(thiophen-3-ylmethyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound S1C=C(C=C1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N CSZGIBWBJCHKBU-HIDXMTOYSA-N 0.000 description 1
- KCSWZGQXMMTEKP-FMZWZIECSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(2-chlorothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC=1SC=CC1CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N KCSWZGQXMMTEKP-FMZWZIECSA-N 0.000 description 1
- FHZXYGAZGCDZBD-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-chlorothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC=1C=C(SC=1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N FHZXYGAZGCDZBD-HIDXMTOYSA-N 0.000 description 1
- NYXVWLZCIYPJGF-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-chlorothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC=1C(=CSC1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N NYXVWLZCIYPJGF-HIDXMTOYSA-N 0.000 description 1
- IUZVYRFLSRYPBY-HPDNKFCTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(5-bromothiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC1=CC=C(S1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N IUZVYRFLSRYPBY-HPDNKFCTSA-N 0.000 description 1
- WWESQQJZMNDQNI-BYPQGEBLSA-N (2R,3R,4S,5R)-2-[6-amino-6-[2-(1H-indol-3-yl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N1C=C(C2=CC=CC=C12)CCC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N WWESQQJZMNDQNI-BYPQGEBLSA-N 0.000 description 1
- UGVIXKXYLBAZND-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(4-hydroxyphenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC(O)=CC=3)=C2N=C1 UGVIXKXYLBAZND-LSCFUAHRSA-N 0.000 description 1
- XQRUUHBPUXOVPD-UHFFFAOYSA-N (4-bromothiophen-2-yl)methanamine Chemical compound NCC1=CC(Br)=CS1 XQRUUHBPUXOVPD-UHFFFAOYSA-N 0.000 description 1
- HHIFWYCYZWPETO-UHFFFAOYSA-N (5-bromothiophen-3-yl)methanol Chemical compound OCC1=CSC(Br)=C1 HHIFWYCYZWPETO-UHFFFAOYSA-N 0.000 description 1
- GQMMRLBWXCGBEV-YVMONPNESA-N (nz)-n-[(3-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC([N+]([O-])=O)=C1 GQMMRLBWXCGBEV-YVMONPNESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 102000007370 Ataxin2 Human genes 0.000 description 1
- 108010032951 Ataxin2 Proteins 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- LLTPEAQWYRBSME-HPDNKFCTSA-N ClC1=C(SC=C1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N Chemical compound ClC1=C(SC=C1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N LLTPEAQWYRBSME-HPDNKFCTSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 102000019055 Nucleoside Transport Proteins Human genes 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000045714 human SLC29A1 Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 230000009427 motor defect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000037831 nucleoside transporters Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- DUDAKCCDHRNMDJ-UHFFFAOYSA-N thiophen-3-ylmethanamine Chemical compound NCC=1C=CSC=1 DUDAKCCDHRNMDJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894699P | 2013-10-23 | 2013-10-23 | |
| US61/894,699 | 2013-10-23 | ||
| PCT/US2014/061734 WO2015061426A1 (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016118282A RU2016118282A (ru) | 2017-11-28 |
| RU2016118282A3 RU2016118282A3 (enExample) | 2018-06-18 |
| RU2695358C2 true RU2695358C2 (ru) | 2019-07-23 |
Family
ID=52993493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016118282A RU2695358C2 (ru) | 2013-10-23 | 2014-10-22 | Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10301348B2 (enExample) |
| EP (1) | EP3060566B1 (enExample) |
| JP (1) | JP6534997B2 (enExample) |
| KR (1) | KR102313314B1 (enExample) |
| CN (1) | CN106414456B (enExample) |
| AU (1) | AU2014340114B2 (enExample) |
| BR (1) | BR112016008901B1 (enExample) |
| CA (1) | CA2927699C (enExample) |
| IL (1) | IL245103B (enExample) |
| MX (1) | MX367707B (enExample) |
| RU (1) | RU2695358C2 (enExample) |
| SG (1) | SG11201603063WA (enExample) |
| WO (1) | WO2015061426A1 (enExample) |
| ZA (1) | ZA201603118B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170544A (es) | 2015-05-29 | 2018-03-20 | Univ Nat Yang Ming | Agentes nucleosidos para la reducción de la actividad perjudicial de los genes que contienen repeticiones de nucleótidos extendidas. |
| WO2018140734A1 (en) | 2017-01-27 | 2018-08-02 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
| AU2023219172B2 (en) * | 2022-02-10 | 2026-02-19 | Academia Sinica | Method of treating spinal cord injury and composition for use therein |
| JP2025520975A (ja) * | 2022-07-07 | 2025-07-03 | 中央研究院 | 統合失調症を治療する方法及びそれにおける使用のための組成物 |
| AU2023416981A1 (en) * | 2022-12-29 | 2025-06-12 | Academia Sinica | Method of treating sleep disruptions and composition for use therein |
| TW202500138A (zh) * | 2023-03-17 | 2025-01-01 | 中央研究院 | 治療結節性硬化症或癲癇之方法及用於其中之組成物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003148A2 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Heteroaromatic derivatives of adenoside |
| EA012703B1 (ru) * | 2002-08-21 | 2009-12-30 | Глэксо Груп Лимитед | Производные пиримидина и их применение в качестве модуляторов cb2 |
| US20120295863A1 (en) * | 2009-11-13 | 2012-11-22 | Yun-Lian Lin | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases |
| WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
| CA2092305C (en) * | 1990-09-25 | 2003-02-11 | Alfred P. Spada | Compounds having antihypertensive and anti-ischemic properties |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| CA2783859A1 (en) | 2009-12-10 | 2011-06-16 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof |
| AU2013216773B2 (en) | 2012-02-09 | 2016-06-09 | Brandbumps, Llc | Decorative detectable warning panel having improved grip |
-
2014
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/en active Active
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/ru active
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/ko active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/pt active IP Right Grant
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/en not_active Ceased
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/ja active Active
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/zh active Active
- 2014-10-22 CA CA2927699A patent/CA2927699C/en active Active
- 2014-10-22 MX MX2016005174A patent/MX367707B/es active IP Right Grant
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003148A2 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Heteroaromatic derivatives of adenoside |
| EA012703B1 (ru) * | 2002-08-21 | 2009-12-30 | Глэксо Груп Лимитед | Производные пиримидина и их применение в качестве модуляторов cb2 |
| US20120295863A1 (en) * | 2009-11-13 | 2012-11-22 | Yun-Lian Lin | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases |
| WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
Non-Patent Citations (2)
| Title |
|---|
| Chemical book on line, CAS RN 214759-22-5 (2008 г) и 79387-71-6 (2010 г). * |
| Wang J. et al, Journal of medicinal chemistry, 19.04.2007, vol. 50, No 8, 1828-1839. GONCALVES N et al, Annals of Neurology, 2013, vol. 73, No5, 655-666. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016535019A (ja) | 2016-11-10 |
| RU2016118282A3 (enExample) | 2018-06-18 |
| AU2014340114A1 (en) | 2016-05-26 |
| EP3060566B1 (en) | 2018-09-05 |
| KR20160086852A (ko) | 2016-07-20 |
| AU2014340114B2 (en) | 2018-10-18 |
| MX2016005174A (es) | 2016-08-11 |
| CN106414456B (zh) | 2018-12-14 |
| CA2927699C (en) | 2022-07-05 |
| CN106414456A (zh) | 2017-02-15 |
| CA2927699A1 (en) | 2015-04-30 |
| BR112016008901B1 (pt) | 2022-08-23 |
| NZ719740A (en) | 2021-02-26 |
| ZA201603118B (en) | 2019-04-24 |
| WO2015061426A1 (en) | 2015-04-30 |
| EP3060566A1 (en) | 2016-08-31 |
| JP6534997B2 (ja) | 2019-06-26 |
| RU2016118282A (ru) | 2017-11-28 |
| IL245103A0 (en) | 2016-06-30 |
| BR112016008901A2 (pt) | 2020-05-12 |
| IL245103B (en) | 2019-02-28 |
| US10301348B2 (en) | 2019-05-28 |
| US20160264613A1 (en) | 2016-09-15 |
| MX367707B (es) | 2019-09-03 |
| KR102313314B1 (ko) | 2021-10-19 |
| SG11201603063WA (en) | 2016-05-30 |
| EP3060566A4 (en) | 2017-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564B1 (en) | Pyridazine derivatives for the treatment of cancer | |
| JP6534997B2 (ja) | 神経変性疾患及び疼痛の予防及び治療における使用のための化合物 | |
| JP6997870B2 (ja) | Ｆｘｒ受容体刺激薬 | |
| US11939319B2 (en) | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | |
| CN104619691B (zh) | 能够调节t-细胞应答的杂环及其使用方法 | |
| Zhang et al. | MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways | |
| JP6991993B2 (ja) | 痛覚過敏を治療する方法 | |
| EP3810587A1 (en) | Substituted alkoxypyridinyl indolsulfonamides | |
| RU2709473C9 (ru) | Тиофеновое соединение, способ его получения и его фармацевтическое применение | |
| TW202140437A (zh) | Sarm1抑制劑 | |
| CA3015947A1 (en) | Bicyclic compounds for diagnosis and therapy of alpha-synuclein associated disorders | |
| CN112057443B (zh) | 苯磺酰胺类化合物的医药用途及其药物组合物 | |
| CN118108716A (zh) | 苯并噻吩类化合物及其制备方法和用途 | |
| CN117279636A (zh) | 用于调节强直性肌营养不良1型的方法和化合物 | |
| ES2950348T3 (es) | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos | |
| US12006321B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | |
| CA3143196A1 (en) | Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same | |
| TWI650328B (zh) | 用於預防及治療神經退化疾病及疼痛之化合物 | |
| TWI668007B (zh) | 用於預防及治療神經退化疾病及疼痛之化合物 | |
| CN112218878A (zh) | Ntcp抑制剂 | |
| WO2024080509A1 (ko) | Igf-1 수용체 결합 압타머 및 이의 용도 | |
| JP2023543089A (ja) | 炎症性障害および自己免疫障害の治療のためのラベキシモド（ｒａｂｅｘｉｍｏｄ）のチオノエステル誘導体 | |
| HK1196035B (en) | Opioid receptor ligands and methods of using and making same | |
| CN106279177A (zh) | 氨基四氢吡喃衍生物作为二肽基肽酶-iv抑制剂 |